Skip to content
value.today

Cynapsus Therapeutics Inc.

Formerly Cannasat Therapeutics Inc.

Total raised
$35 M
3 rounds on record
Latest round
$17 M
Mar 2015
First round on record
Mar 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cynapsus Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2015$17 MNo. 3$10 to $50 million

Cynapsus Therapeutics Inc.: Raise no. 3, Mar 2015

Investors in this round

14 investors had bought by the notice of Apr 14, 2015: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,005,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Andrew Williams · Executive Officer
  • Anthony Giovinazzo · Executive Officer, Director
  • Thierry D. Bilbault · Executive Officer
  • Ilan Nan Oren · Director
  • Margaret Nan Hutchinson · Director
  • Perry Nan Molinoff · Director
  • Rochelle D. Stenzler · Director
  • Ronald Hosking · Director
  • Tamar D. Howson · Director
  • Tomer Gold · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble Financial Capital Markets (CRD 15768) · Boca Raton, FloridaSold in CA, NY

Signed by Andrew Williams, Chief Operating Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 14, 2015. Read the notice at the SEC.

equitySEC
Apr 2014$15 MNo. 2$10 to $50 million

Cynapsus Therapeutics Inc.: Raise no. 2, Apr 2014

Investors in this round

19 investors had bought by the notice of Apr 21, 2014: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $43 M offered; $28 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit is comprised of one common share and one share purchase warrant. Each warrant is exercisable for one common share at an exercise price of Cdn$0.81 for a period of 60 months.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
$1,018,240
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Andrew Williams · Executive Officer
  • Anthony Giovinazzo · Executive Officer, Director
  • Alan D. C. Ryley · Director
  • Ilan Oren · Director
  • Nan Hutchinson · Director
  • Perry Molinoff · Director
  • Rochelle D. C. Stenzler · Director
  • Ronald Hosking · Director
  • Tomer Gold · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maddie King III (CRD 2784584) · broker-dealer Brookline Group, LLC (CRD 153587) · Birmingham, AlabamaSold in CA, FL, IL, NY
  • Noble Financial Capital Markets (CRD 15768) · Boca Raton, FloridaSold in CA, FL, IL, NY

Remarks in the notice

  • On fees: “The agent also received warrants exercisable for approximately 1,720,199 shares of common stock of the issuer at a price of Cdn$0.81 per share for a period of 60 months with respect to the U.S. portion of the offering.”
  • On the amounts: “The additional $28,370,682 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchage report on April 15, 2014, which was CN$1.0981=US$1.00.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Andrew Williams, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 21, 2014. Read the notice at the SEC.

equity, optionsSEC
Mar 2013$4 MNo. 1$2 to $10 million

Cynapsus Therapeutics Inc.: Raise no. 1, Mar 2013

Investors in this round

5 investors had bought by the notice of Mar 27, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $13 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit it comprised of one common share and one common share purchase warrant. Each warrant is exercisable for one common share at an exercise price of Cdn$0.575 per share for a period of 60 months
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
$101,664
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • Andrew Williams · Executive Officer
  • Anthony Giovinazzo · Executive Officer, Director
  • Nathan Bryson · Executive Officer
  • Alan D. C. Ryley · Director
  • Alan D. C. Torrie · Director
  • Julia Levy · Director
  • Perry Molinoff · Director
  • Rochelle D. C. Stenzler · Director
  • Ronald Hosking · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Moody Capital Solutions, Inc. (CRD 15989) · broker-dealer M Partners Inc. · Dawsonville, GeorgiaSold in CA
  • Brookline Group, LLC (CRD 153587) · broker-dealer M Partners Inc. · Birmingham, AlabamaSold in AL

Remarks in the notice

  • On fees: “The underwriters also received broker warrants exercisable for approximately 1,962,087 shares of common stock of the issuer at a price of Cdn$0.575 per share for a period of 60 months with respect to the U.S. portion of the offering.”
  • On the amounts: “The additional $8,893,457 may be received upon exercise of share purchase warrants sold both inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on March 1, 2013, which was Cdn$1.0285=US$1.00.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds to pay salaries to certain of its executive officers and directors.”

Signed by Andrew Williams, Chief Financial Officer and Chief Operations Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 27, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cynapsus Therapeutics Inc. had no revenue when it filed its newest notice of a funding round (Apr 2015).

    SEC Form D (revenue range) · Apr 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2015

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cynapsus Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cynapsus Therapeutics Inc.
NameRoleNamed in
Andrew WilliamsExecutive officerApr 2015
Anthony GiovinazzoExecutive officerApr 2015
Thierry D. BilbaultExecutive officerApr 2015
Nathan BrysonExecutive officerMar 2013
Anthony GiovinazzoDirectorApr 2015
Ilan Nan OrenDirectorApr 2015
Margaret Nan HutchinsonDirectorApr 2015
Perry Nan MolinoffDirectorApr 2015
Rochelle D. StenzlerDirectorApr 2015
Ronald HoskingDirectorApr 2015
Tamar D. HowsonDirectorApr 2015
Tomer GoldDirectorApr 2015
Alan D. C. RyleyDirectorApr 2014
Ilan OrenDirectorApr 2014
Nan HutchinsonDirectorApr 2014
Perry MolinoffDirectorApr 2014
Rochelle D. C. StenzlerDirectorApr 2014
Alan D. C. TorrieDirectorMar 2013
Julia LevyDirectorMar 2013